Global Alzheimer Treatment Market Size, Forecast, and Trend Highlights Over 2025-2037
Alzheimer Treatment Market size was valued at USD 1.6 billion in 2024 and is likely to cross USD 3.9 billion by 2037, registering more than 7.7% CAGR during the forecast period, i.e., between 2025-2037. In 2025, the industry size of alzheimer treatment is estimated at USD 1.7 billion.
According to the 2023 NLM predictions, the worldwide populations of patient pools for dementia, prodromal, and preclinical conditions associated with Alzheimer’s (AD) were 32.0 million, 69.0 million, and 315.0 million, respectively. It further mentioned that over 22.0% of the total AD figure belonged to the age group of 50 and above. Many studies have established the close association of disease severity with age progression, where WHO projected the global number of people aged 60 and over to be 2.1 billion by 2050. Thus, these continuously growing figures signify the inflation in the need for effective treatment and prevention, propelling growth in the market.
The market has witnessed significant growth in recent years, which is attributed to the improvements in healthcare infrastructure. The growing investments in the healthcare sector have raised a significant amount of funds to support ongoing research projects, propelling innovation in this field. For instance, in June 2020, the National Institute on Aging (NIA) allocated USD 75.8 million to Cognition Therapeutics for supporting the ongoing five-year phase II study on a small molecule, CT1812, for AD treatment. Further, the total value of NIA’s 600 small business R&D investments till August 2021 (in the last 11 years) was calculated to be USD 280.0 million. Another 2021 NLM study concluded that the net private R&D fund in this discipline accounted for USD 42.5 billion from 1995.
Alzheimer Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Improved efficacy of dedicated therapeutics: The Introduction of precision medicine, brain stimulation therapies, and AI-powered wearables have revolutionized the productivity of the alzheimer treatment market. With the focus on early intervention, many pharma pioneers are engaging their resources to develop more specific and efficient curatives. For instance, in May 2023, Eli Lilly and Company achieved positive endpoints from the TRAILBLAZER-ALZ 2 Phase 3 study on donanemab. The results demonstrated the promising potential of this targeted therapy in slowing cognitive and functional decline in early symptomatic AD.
- Steady capital influx for global expansion: Increasing economic and healthcare burdens all over the world are influencing leaders in the market to expand their reach overseas. Their efforts to globalize the product pipeline bring diversity and improve accessibility in the emerging landscapes of this sector. For instance, in January 2025, Alpha Cognition secured USD 44.0 million from the exclusive licensing agreement with China Medical System Holdings Limited. The agreement encompasses the development, manufacturing, and commercialization of ZUNVEYL (benzgalantamine) across Asia, Australia, and New Zealand as a first-line treatment of mild-to-moderate AD.
Challenges
- Financial and compliance volatility in clinical trials: Increasingly stringent regulations and limited testing procedures are predicted to act as barriers for the alzheimer treatment market. The high standards and long-term safety evaluation required for the approval of any drug or device for treatment may create obstacles for the manufacturers. In addition, greater chances of failure during clinical trials may also discourage companies from investing and engaging in extensive R&D. This may restrict innovations and progression in this sector.
- Limitation in resources and skills: The biological complexity of AD often creates obstacles for drug developers in the market. Hiring professionals with proper knowledge about the disease mechanisms and manufacturing process may become difficult for biopharma companies. Additionally, securing a reliable supply channel for specific raw materials is also a challenging task for exploration projects in resource-constrained regions. This may limit the manufacturers from examining the benefits of various new compounds, limiting growth.
Alzheimer Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.7% |
|
Base Year Market Size (2024) |
USD 1.6 billion |
|
Forecast Year Market Size (2037) |
USD 3.9 billion |
|
Regional Scope |
|
Alzheimer Treatment Segmentation
End user (Hospitals, Clinics, Nursing Homes, Home-Care Settings)
On the basis of end user, the hospitals segment is anticipated to hold the largest share by 2037 as a result of rising AD-related hospital admissions for better care. According to a CDC survey, 37.2% of emergency visits by adult AD patients in the U.S. converted into hospital admissions during the period between 2020 and 2022. The well-equipped infrastructure and dedicated specialized departments present in most of the medical settings in developed countries make these organizations the first contact point for every individual. Thus, the contribution of this segment in generating revenue from the market is higher than other healthcare premises.
Drug Class (Standalone Drugs, Combination Drugs)
On the basis of drug class, the combination drugs segment is predicted to register the fastest pace of growth over the forecast period. The combination therapies are predicted to improve the condition of the patients significantly as compared to the standalone therapies. The drugs used in combination therapies are considered to have better efficacy, owing to the higher potential of the conjugated terms of reaction. This kind of therapy is currently considered to be highly effective in treating moderately severe Alzheimer’s disease. For instance, an observational study was published by the Journal of Controlled Release in March 2024, highlighting significant improvement in social and cognitive aspects of AD candidates over the use of combined therapy, incorporating memantine and donepezil.
Our in-depth analysis of the global alzheimer treatment market includes the following segments:
|
End user |
|
|
Drug Class |
|
|
Distribution Channel |
|
|
Product |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAlzheimer Treatment Industry - Regional Synopsis
North American Market Forecast
North America is expected to hold the majority share of the alzheimer treatment market by 2037 on account of increasing incidences of the disease. With the presence of many key players in the region, the region is further predicted to expand rapidly, backed by ongoing technological advancements in the field. Academic excellence is also highly observed across various medicinal institutions, which is solidifying the region’s leadership internationally. For instance, in December 2023, a team of researchers at the Perelman School of Medicine at the University of Pennsylvania identified the potential of chemical chaperone in reversing the signs of AD. This fatty-acid molecule effectively slows the formation of certain proteins, causing memory impairment.
The market in the U.S. is estimated to hold a vast potential for development, influenced by its increasing geriatric population, which is contributing significantly to the occurrence of the disease. In 2022, AD was identified to be the 7th most deadly disease in this country, affecting nearly 6.5 million citizens aged 65 and over, as per the estimations from the CDC. Furthermore, the efforts from the governing bodies to spread awareness about early detection, treatment options, and management tools are fueling this landscape.
APAC Market Forecast
The Asia Pacific alzheimer treatment market is expected to grow steadily over the analyzed period, which is attributed primarily to the rising elderly population in countries including India, China, Australia, and Japan. The increasing prevalence of the disease among the elderly is the major factor that is expected to drive the growth of this landscape in upcoming years. According to a report from the United Nations, the number of people aged 60 and over in Asia Pacific is estimated to be at 1.3 billion by 2050. Similarly, the region’s proportion in the 80 and above age group population worldwide is projected to become 59.0% by the same timeline. This signifies an enlarging patient pool, propelling the sector’s expansion.
China has a large patient pool and a technologically progressive culture in healthcare, indicating a strong emphasis on the market. The demography of this country is pushing both public and private organizations to cultivate a sufficient resource of effective treatment options. This is creating lucrative opportunities for dedicated domestic and foreign suppliers. For instance, in June 2024, Eisai and Biogen collaboratively launched a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, LEQEMBI, for AD in China.
Companies Dominating the Alzheimer Treatment Landscape
- NeuroEM Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AbbVie Inc.
- Allergan Inc.
- H. Lundbeck A/S
- Janssen
- Eli Lilly and Company
- Daiichi Sankyo Company Limited
- Eisai Co., Ltd.
- Neuronix.
The alzheimer treatment market is evolving with the innovations in precision medicine and targeted therapies. Key players in this sector are engaging in rigorous R&D to improve the efficacy of their product pipeline and expand their reach globally. This tendency is attracting other competitors to invest in new exploration cohorts, contributing to the progression and expansion of this field. Moreover, their efforts to participate in large-scale international trading are extending market exposure and creating greater opportunities for new entrants. Such key players are:
In the News
- In January 2025, Eisai Co. attained Supplemental Biologics License Application (sBLA) approval from the FDA for once every four weeks LEQEMBI IV dosing, in collaboration with Biogen. The clearance expanded the company’s portfolio in treating Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage.
- In July 2024, Eli Lilly and Company gained FDA approval for the use of donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion to treat early symptomatic Alzheimer's disease. Kisunla has been clinically proven to be effective in lowering treatment costs and infusion counts with its ability to stop therapy when amyloid plaques are removed.
Author Credits: Radhika Pawar
- Report ID: 2384
- Published Date: Apr 10, 2025
- Report Format: PDF, PPT
